IBM’S watson tackles lung cancer Originally published: February 12, 2013 8:56 AM Updated: February 12, 2013 9:14 AM By KEN SCHACHTER [email protected]   IBM’s Watson may not be hanging up a shingle, but the supercomputer will help doctors at New York-based Memorial Sloan-Kettering Cancer Center evaluate patients’ lung cancer treatments. Armonk-based IBM said Watson, which… Read More

New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials Abstract We summarize significant changes in pathologic classification of lung cancer resulting from the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) lung adenocarcinoma classification. The classification was developed by an international core panel of experts… Read More

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell Lung Cancer Abstract Background: The presence of mutation in EGFR gene is known as a predictive marker for the response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment. However,… Read More